AAAAAA
Results:
1-7
|
Results: 7
Authors:
Gutheil, J
Citation: J. Gutheil, Monoclonal antibodies and cancer, CR R ONC H, 40(1), 2001, pp. 1-2
Authors:
Gutheil, J
Citation: J. Gutheil, The promise of monoclonal antibodies for the therapy of cancer, CR R ONC H, 38(1), 2001, pp. 1-2
Authors:
Batist, G
Ramakrishnan, G
Rao, CS
Chandrasekharan, A
Gutheil, J
Guthrie, T
Shah, P
Khojasteh, A
Nair, MK
Hoelzer, K
Tkaczuk, K
Park, YC
Lee, LW
Citation: G. Batist et al., Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer, J CL ONCOL, 19(5), 2001, pp. 1444-1454
Authors:
Saleh, MN
Gutheil, J
Moore, M
Bunch, PW
Butler, J
Kunkel, L
Grillo-Lopez, AJ
LoBuglio, AF
Citation: Mn. Saleh et al., A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia, SEMIN ONCOL, 27(6), 2000, pp. 99-103
Authors:
Gutheil, J
Finucane, D
Citation: J. Gutheil et D. Finucane, Thalidomide therapy in refractory solid tumour patients, BR J HAEM, 110(3), 2000, pp. 754-754
Authors:
Wiseman, GA
White, CA
Witzig, TE
Gordon, LI
Emmanouilides, C
Raubitschek, A
Janakiraman, N
Gutheil, J
Schilder, RJ
Spies, S
Silverman, DHS
Grillo-Lopez, AJ
Citation: Ga. Wiseman et al., Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a Y-90-labeled anti-CD20 monoclonal antibody, CLIN CANC R, 5(10), 1999, pp. 3281S-3286S
Authors:
Witzig, TE
White, CA
Wiseman, GA
Gordon, LI
Emmanouilides, C
Raubitschek, A
Janakiraman, N
Gutheil, J
Schilder, RJ
Spies, S
Silverman, DHS
Parker, E
Grillo-Lopez, AJ
Citation: Te. Witzig et al., Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsedor refractory CD20(+) B-cell non-Hodgkin's lymphoma, J CL ONCOL, 17(12), 1999, pp. 3793-3803
Risultati:
1-7
|